Similarly, in our cohort, BRCA1/2 mutations were present in tumors without PARPi approval, such as endometrial, lung, colon, and biliary tract tumors, as well as in the case of a tumor of unknown primary origin. This evidence concerns the gene BRCA1 and neoplasm.